Lilly expands its Zepbound vial offering, as Hims pulls back on semaglutide
Lilly expands its Zepbound vial offering, as HIMS pulls back on semaglutide, and other biotech news in today's Readout newsletter.
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Good morning. A bunch of people I know (including me) have gotten sick recently. It’s a particularly intense flu season right now. Hope everyone is taking care of themselves.
